Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 390 participants.
Also called NCT07286747
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 390 participants
- Registry
-
NCT07286747 -
2024-519903-88-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Germany
- Registry status
- Recruiting
Technical summary
Registry record NCT07286747. Randomized; triple masking; primary purpose prevention. Start 2026-03-03 (actual); primary completion 2028-05-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)
- Acronym
- CONCEPT
- Condition
- Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
- Intervention (Drug)
- controlled-ileal-release nicotinic acid as multiple dose 100 mg/day
- Intervention (Drug)
- controlled-ileal-release nicotinic acid as multiple dose 200 mg/day
- Intervention (Drug)
- controlled-ileal-release nicotinic acid as multiple dose placebo
- Lead sponsor
- University Hospital Schleswig-Holstein
Record details
- Record id
cardio:ct-nct07286747- Content hash
a32e0b7656427432952eec63b07e8eb5b5b7e596037ba265176a7b828ba609ae